Market Overview

Bonti Announces Scientific Presentation at Premier Aesthetic Plastic Surgery Conference

Share:

EB-001T and EB-001A To Be Spotlighted at The Aesthetic Meeting 2018

Bonti, Inc., an innovative clinical-stage biotechnology company focused
on the development and commercialization of novel, fast-acting
neurotoxin products for therapeutic and aesthetic applications, today
announced a Hot Topics presentation for its therapeutic product
candidate, EB-001T, and for its aesthetic product candidate, EB-001A, at
the American Society for Aesthetic Plastic Surgery (ASAPS) The Aesthetic
Meeting 2018, beginning April 26 in New York City, New York. EB-001, the
active ingredient in both EB-001T and EB-001A, is derived from botulinum
neurotoxin serotype E (BoNT/E) and is designed to have a clinical
profile with a faster onset of efficacy (within 24 hours) and a shorter
duration of activity (2 to 4 weeks) than botulinum neurotoxin
serotype A (BoNT/A) products. EB-001T and EB-001A are being developed to
address areas of unmet therapeutic and aesthetic need.

The Aesthetic Meeting 2018 Hot Topics presentation will be delivered by
Dr. Alan Matarasso, a renowned aesthetic plastic surgeon and current
Bonti Medical Advisor. It will feature BoNT/E as an innovative
neurotoxin candidate for therapeutic and aesthetic applications.
Highlights will include descriptions of the ongoing clinical trial of
EB-001T in the mammoplasty model, the planned Phase 2 clinical trial of
EB-001T in the abdominoplasty model and the ongoing Phase 2a clinical
trial of EB-001A for scar reduction following Mohs micrographic surgery.

"We're excited to have EB-001T and EB-001A presented at this prestigious
conference in April as we continue to gather more data on these product
candidates and further expand the scope of sharing the findings within
the medical community," said Fauad Hasan, CEO and co-founder at Bonti.
"We appreciate the ASAPS for selecting EB-001T and EB-001A for this
opportunity and are honored to have Dr. Matarasso share potential
prospects of our product candidates with his colleagues."

About EB-001

Bonti is developing a first-in-class pipeline of proprietary product
candidates derived from BoNT/E. BoNT/E, from which the active ingredient
in Bonti's product candidates is derived, has a validated mechanism of
action similar to that of currently approved products derived from
BoNT/A, but, based on preclinical and clinical data, BoNT/E has a faster
onset of efficacy (within 24 hours) and a shorter duration of activity
(2 to 4 weeks) compared to BoNT/A products, which have an onset of
efficacy of approximately 3 to 7 days and a duration of activity of
approximately 3 to 4 months. Based on this differentiated clinical
profile, Bonti's therapeutic product candidate, EB-001T, is being
developed for the treatment of focal muscle pain, and Bonti's aesthetic
product candidate, EB-001A, is being initially developed for glabellar
frown lines and for scar reduction following Mohs surgery.

About Bonti

Bonti, based in Newport Beach, CA, is an innovative clinical-stage
biotechnology company focused on the development and commercialization
of novel, fast-acting neurotoxin products for therapeutic and aesthetic
applications. The company was founded and is led by executives with
extensive experience obtained at Allergan plc with botulinum neurotoxin
products from discovery, clinical, supply chain, regulatory and
commercialization perspectives. By turning the science of neurotoxins
into beneficial patient and healthcare provider solutions, Bonti seeks
to improve lives by successfully addressing key unmet needs in markets
with significant addressable opportunities.

For more information, please visit http://bonti.com.

View Comments and Join the Discussion!